

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/033635 A1

- (51) International Patent Classification⁷: **C11D 3/50**, A61L 9/01, C11D 3/30, 3/33, 3/37
- (21) International Application Number: **PCT/US02/33377**
- (22) International Filing Date: 18 October 2002 (18.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/345,469 19 October 2001 (19.10.2001) US
- (71) Applicant: **THE PROCTER & GAMBLE COMPANY** [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).
- (72) Inventors: **DYKSTRA, Robert, Richard**; 7715 Mitchell Park Drive, Cleves, OH 45002 (US). **GRAY, Lon, Montgomery**; 1806 Promontory Drive, Florence, KY 41042 (US). **MIRACLE, Gregory, Scot**; 3065 Old Oxford Road, Hamilton, OH 45013 (US). **GALLON, Lois, Sara**; 642 Reynard Avenue, Cincinnati, OH 45224 (US). **MALTON, Peter, James**; 22 The Glade, Staines, Middlesex TW18 1EW (GB).
- (74) Agents: **REED, T., David et al.**; The Procter & Gamble Company, 6110 Center Hill Rd., Cincinnati, OH 45224 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/033635 A1

(54) Title: **CONTROLLED BENEFIT AGENT DELIVERY SYSTEM**

(57) Abstract: The present invention relates to a benefit agent delivery system, comprising a benefit agent and an amine comprising a primary and/or secondary amine moiety that can, when directly applied to a substrate, provide a longer benefit term than when a benefit agent alone is applied to said substrate. Typical benefit agents include perfume raw materials such as perfume aldehydes and ketones.

CONTROLLED BENEFIT AGENT DELIVERY SYSTEM

Field of the Invention

The present invention relates to benefit agent delivery systems that, when directly applied to a substrate, provide a longer benefit term than the benefit agent alone.

Background of the Invention

It is frequently desirable or advantageous to treat the surfaces of a variety of substrates, for example fabrics, with benefit agents such as perfumes, flavors, pharmaceuticals and/or biocontrol agents including biocides, insecticides, mildewcides, and the like. Generally, the objective of such treatment is to leave deposited on the surfaces of the substrates enough benefit agent so that there is a residual benefit imparted to the substrate surface.

Products, systems and methods for depositing benefit agents onto the surfaces of substrates are known in the art. For example, in the context of fabric treatment, such as fabric laundering, a variety of products can be used to form benefit imparting aqueous washing liquors or rinse baths.

Other products that provide improved deposition onto substrate surfaces are benefit agents such as perfumes. Such products are described in PCT Patent Application Nos. WO 00/02991; WO 00/02981; WO 00/02987 and WO 00/02982. These patent publications disclose compositions wherein a residual benefit agent is realized by incorporating a reaction product formed from amine-based compounds and certain types of benefit agents that will react with such amine-based compounds into substrate treatment products.

However, notwithstanding the advances in the art, there remains a continuing need for benefit agent delivery systems that are especially effective for directly delivering residual and long-lasting benefit agents to substrates.

Summary of the Invention

The present invention relates to a benefit agent delivery system suitable for delivering a benefit agent to a substrate, wherein the benefit agent delivery system

comprises a benefit agent and an amine comprising an amine moiety selected from the group consisting of primary amines, secondary amines and mixtures thereof, such that when said amine and said benefit agent are directly applied to a substrate, the benefit agent provides a benefit to the substrate for a longer period of time than when said amine is not present.

The present invention also relates to products comprising the aforementioned delivery system and methods of using same.

Detailed Description

Applicants' benefit delivery systems provide formulation flexibility as initial and ongoing benefit release levels can be adjusted to achieve almost any type of release profile, including profiles that are consistent with time. For example, in one aspect of Applicants' invention the amount of benefit agent that is initially released is perceptibly less than that normally released, however, such release rate is more consistent with time. In the event that a combination of high initial and sustained release is desired, the skilled artisan need only alter the level or mix of the one or more of benefit agents employed. In general, the benefit agent and amine component of the present invention should be in intimate contact for a sufficient period of time, before being applied, to provide the optimum benefit. While such contact period may vary from application to application, Applicants' have discovered that a seven day contact period is sufficient for most applications.

The components of the benefit agent delivery systems herein are selected and processed such that the resulting delivery systems are especially effective for delivering the benefit agent to a substrate that has been directly contacted with delivery system. Under such conditions, the benefit agent delivered to the substrate surface will provide its benefit thereto for a longer period of time than if no amine-based compound were present in the delivery system.

The benefit agent delivery systems of the present invention are particularly useful in various applications and/or products that are intended to be applied without dilution, such as fine fragrance perfume applications and/or products, home care perfume products, such as freshening compositions, that may comprise cyclodextrins, and that are typically

applied to upholstery, carpets and other fabric articles, hard surface treating compositions, beauty care applications, such as creams, lotions, deodorants, antiperspirants, and other topical compositions, hair care compositions, such as hair spray, leave-in conditioners, and the like.

Definitions and Test Methods:

“Directly applied” and/or “delivering directly” as used herein means that a benefit agent is applied to a substrate via the benefit agent delivery system such that the benefit provided by the benefit agent is realized and/or recognized prior to dilution. For example, a benefit agent is sprayed onto a substrate and/or wiped on to a substrate, rather than having the benefit agent contact or deposit indirectly onto a substrate from a dilute solution (i.e., wash liquor).

The term “unit which can substitute for hydrogen” means “chemical moieties which can replace a hydrogen atom on a hydrocarbon chain, an aryl ring, and the like, or replace a hydrogen atom, two hydrogen atoms, or three hydrogen atoms from a carbon atom to form a moiety, or replace hydrogen atoms from adjacent carbon atoms to form a moiety.” For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. Three hydrogen replacement includes cyano, and the like.

The term “substituted” means that a moiety, *inter alia*, aromatic ring, alkyl chain, can have one or more of the hydrogen atoms replaced by a substituent. For example, 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”, and 3-guanidinopropyl is a “substituted C₃ alkyl unit.”

The term “hydrocarbyl” means “any unit which comprises carbon and hydrogen atoms, whether linear, branched, cyclic, and regardless of how many of the hydrogen atoms are substituted with a suitable “substituted” unit.” Non-limiting examples of “hydrocarbyl” units include methyl, benzyl, 6-hydroxyoctanyl, m-chlorophenyl, 2-(N-methylamino)propyl, and the like. The following are non-limiting examples of moieties, which can replace hydrogen atoms on carbon to form a “substituted hydrocarbyl” unit:

- i) $-\text{NHCOR}^{30}$;
- ii) $-\text{COR}^{30}$;
- iii) $-\text{COOR}^{30}$;
- iv) $-\text{COCH}=\text{CH}_2$;
- v) $-\text{C}(=\text{NH})\text{NH}_2$;
- vi) $-\text{N}(\text{R}^{30})_2$;
- vii) $-\text{NHC}_6\text{H}_5$;
- viii) $=\text{CHC}_6\text{H}_5$;
- ix) $-\text{CON}(\text{R}^{30})_2$;
- x) $-\text{CONHNH}_2$;
- xi) $-\text{NHCN}$;
- xii) $-\text{OCN}$;
- xiii) $-\text{CN}$;
- xiv) F, Cl, Br, I, and mixtures thereof;
- xv) $=\text{O}$;
- xvi) $-\text{OR}^{30}$;
- xvii) $-\text{NHCHO}$;
- xviii) $-\text{OH}$;
- xix) $-\text{NHN}(\text{R}^{30})_2$;
- xx) $=\text{NR}^{30}$;
- xxi) $=\text{NOR}^{30}$;
- xxii) $-\text{NHOR}^{30}$;
- xxiii) $-\text{CNO}$;
- xxiv) $-\text{NCS}$;
- xxv) $=\text{C}(\text{R}^{30})_2$;
- xxvi) $-\text{SO}_3\text{M}$;
- xxvii) $-\text{OSO}_3\text{M}$;
- xxviii) $-\text{SCN}$;
- xxix) $-\text{P}(\text{O})\text{H}_2$;
- xxx) $-\text{PO}_2$;
- xxxi) $-\text{P}(\text{O})(\text{OH})_2$;

- xxxii) $-\text{SO}_2\text{NH}_2$;
- xxxiii) $-\text{SO}_2\text{R}^{30}$;
- xxxiv) $-\text{NO}_2$;
- xxxv) $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CBr}_3$;
- xxxvi) and mixtures thereof;

wherein R^{30} is hydrogen, C_1 - C_{20} linear or branched alkyl, C_6 - C_{20} aryl, C_7 - C_{20} alkylenearyl, and mixtures thereof; M is hydrogen, or a salt forming cation. Suitable salt forming cations include, sodium, lithium, potassium, calcium, magnesium, ammonium, and the like. Non-limiting examples of an alkylenearyl unit include benzyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl.

The term "inorganic carrier", means a carrier that comprises of non- or substantially non-carbon based backbones.

Odor Intensity Index Method: Odor Intensity Index is a value determined by expert graders who evaluate test chemicals for odor when such the pure chemicals are diluted at 1% in dipropylene glycol (DPG), odor-free solvent used in perfumery. This concentration percentage is representative of typical usage levels. Smelling strips, or so called "blotters", are dipped in test solutions and presented to expert panelists for evaluation. Expert panelists are assessors trained for at least six months in odor grading and whose gradings are checked for accuracy and reproducibility versus a reference on an on-going basis. For each amine compound, a panelist is presented two blotters: one reference (Me Anthranilate, unknown from the panelist) and the test sample. The panelist is asked to rank both smelling strips on the 0-5 odor intensity scale, 0 being no odor detected, 5 being very strong odor present.

The following represents Odor Intensity Index of some amine compounds suitable for use in the present invention. In each case, numbers are arithmetic averages among 5 expert panelists and the results are statistically significantly different at 95% confidence level:

Methylantranilate 1% (reference)	3.4
Ethyl-4-aminobenzoate (EAB) 1%	0.9
1,4-bis-(3-aminopropyl)-piperazine (BNPP) 1%	1.0

Protocol 1.1 – Longevity Test: Each benefit delivery system that comprises a perfume raw material and an amine, is tested in accordance with the instant protocol. Each perfume aldehyde or ketone (P) found in such perfume raw material is tested with each amine to determine if the combination (PA) demonstrates a longevity that is greater than that obtained for P alone.

Multiple benefit agents may be tested together, at the same time, in the presence of multiple amines, as long as the analytical measurements are not compromised by such combination. By way of illustration, a benefit delivery system that contains six perfumes — three of which are aldehyde or a ketone perfumes (P^1 , P^2 and P^3), and three of which are not aldehyde or ketone perfumes, and a single amine (A^1) requires the following single-variable test: (P^1A^1 , P^2A^1 and P^3A^1) verses (P^1 , P^2 and P^3), provided that said benefit agents are chromatographically separable such that the amount of each perfume aldehyde or ketone is easily determined in the presence of the other. Perfume aldehydes or ketones that are not chromatographically separable from one another must be run in separate tests. If, for example, P^1 and P^3 are not separable, then one of the following sets of tests is required:

- I. (P^1A^1 and P^2A^1) vs. (P^1 and P^2), and (P^3A^1) vs. (P^3); or
- II. (P^2A^1 and P^3A^1) vs. (P^2 and P^3), and (P^1A^1) vs. (P^1); or
- III. (P^1A^1) vs. (P^1), and (P^2A^1) vs. (P^2), and (P^3A^1) vs. (P^3).

No P in any test should be present at a concentration greater than ten times the concentration of another P in the same test. In such a case, separate tests are indicated.

- a.) Determination of the Concentration of Benefit Agent(s) and Amine in the Test Solution

The absolute concentration for the test solution (TS) to be used in a Benefit Agent Longevity Test (LT) is determined as follows.

The perfume aldehyde(s) or ketone(s) and amine(s) that are to be tested together are dissolved in 50:50 (v/v) ethanol:water at a concentration equal to that used in the benefit agent delivery system. The solution is closed to the atmosphere and aged for 24 hours at room temperature to obtain the initial test solution, designated TS_0 . A 1.0 mL aliquot of TS_0 is pipetted onto a 4 cm diameter circle weighing 0.45 – 0.65 g (weight of circles in a given test should be the same ± 0.02 g) cut from an 86/14 cotton/poly terry wash cloth (obtained from EMC, 7616 Reinhold Drive, Cincinnati, OH 45237). The cloth, charged with test solution, is left open to the atmosphere under ambient conditions and subsequently analyzed via headspace gas chromatography (HSGC) to determine the amount of each perfume aldehyde or ketone in the headspace at each of the following times: 0.50, 1, 2, 4, 6, 8, and 24 hours.

The absolute concentration of perfume aldehyde(s) or ketone(s) and amine(s) to be used in the LT is the lowest concentration in a series of solutions based on TS_0 at which each perfume aldehyde or ketone in the TS is detected by HSGC at no less than one of the designated time points. If this condition is not met by TS_0 , the concentration of the test solution is doubled and the new solution (TS_1) is tested in the same manner. The process is repeated until the condition is met. The concentration of perfume aldehyde(s) or ketone(s) and amine(s) in the test solution that meets the expressed condition (TS_n) is related to the concentration of the perfume aldehyde(s) or ketone(s) and amine(s) in TS_0 according to the following equation:

$$[P, A] \text{ in } TS_n = 2^n \cdot [P, A] \text{ in } TS_0; \text{ where } n = 0, 1, 2, 3 \dots$$

b.) Headspace Gas Chromatography

Equipment required consists of:

- 1.) A trap containing a porous polymer having the ability to retain aroma materials, preferably Tenax TA 35/60 mesh.
- 2.) A source of pure helium.

3.) A headspace collector to contain the fabric circle and allow benefit agent to partition into the vapor headspace and reach equilibrium.

4.) GC-MS with headspace capabilities.

Suitable equipment is as referenced in S. Maeno, P.A. Rodriguez. J. Chromatography, A731 (1996) 201-215. It consists of equipment to transfer the equilibrated headspace vapors containing perfume aldehydes or ketones, which have been captured on a porous polymer, onto a GC for quantitative analysis. This equipment is able to heat the porous polymer trap containing the collected headspace, transferring the vapors to a cold trap cooled to $< -100\text{ }^{\circ}\text{C}$ (generally by liquid nitrogen). Following complete transfer to the cold trap, the cold trap is flash heated in a short period of time—typically about 1 minute—to a temperature of approximately $0\text{ }^{\circ}\text{C}$ followed by a normal temperature gradient to about $280\text{ }^{\circ}\text{C}$, resulting in the transfer of the headspace vapors directly onto a capillary GC column. A typical column is a 30 – 60 meter long with an i.d. of 0.18 – 0.32 mm, with a stationary phase composed of 100% dimethylpolysiloxane or (5%-phenyl)-methylpolysiloxane. The GC has the capability of quantitating and identifying said perfume aldehydes or ketones. Identification is accomplished via Mass Spectrometry and quantification is performed using a separate detector, such as an FID (flame ionization) or PID (photo ionization) detector.

c.) Longevity Test

A given test solution TS_n meeting the condition described above is prepared. A second test solution TS_c is prepared containing all the components of TS_n at exactly the same concentrations as in TS_n except that any amines have been removed. TS_c serves as the control solution in the test.

Data is gathered for a given test solution (either TS_c or TS_n) as follows: A 1.0 mL aliquot of TS is pipetted onto a 4 cm diameter circle cut from an

86/14 cotton/poly terry wash cloth. The cloth charged with TS is left open to the atmosphere under ambient conditions and subsequently analyzed via headspace gas chromatography (HSGC) to determine the amount of each benefit agent in the headspace at each of the following seven designated times: 0.50, 1, 2, 4, 6, 8, and 24 hours.

The conditions used for the analysis in each case are identical. The only difference for the two sets of data is that one set is obtained from a solution containing amine and the other set is obtained from a solution not containing amine.

A longevity benefit is confirmed for a particular P when the quantitative amount of the P in the headspace from TS_n at any one of the seven designated times points is greater (statistically significant at 95% confidence) than the amount of the same P in the headspace from TS_c at the corresponding time point.

d.) Example Results

The following table demonstrates the type of results that can be obtained from a Longevity Test. The data confirms a longevity benefit for P^1 (at $t = 4$ h, the area count from $TS_n > TS_c$) and P^2 (at $t = 1$ h, the area count from $TS_n > TS_c$) in the presence of A^1 .

Time (h)	HSGC Area Count for Benefit Agent with and without A^1					
	P^1		P^2		P^3	
	TS_c	TS_n	TS_c	TS_n	TS_c	TS_n
0.50	12000	1000	8000	2000	30000	26000
1	6000	1500	400	1500	5000	4500
2	3000	2500	20	1000	850	700
4	1500	4000	ND	500	140	90
6	750	1500	ND	150	25	ND

8	220	500	ND	30	ND	ND
24	ND	50	ND	ND	ND	ND

ND = Not detected.

Amine


Applicants discovered that non-aromatic amines provide Applicants' delivery system with especially effective and efficient release characteristics. While not being bound by theory, Applicants believe that such characteristics are due to the substantial difference in the pKa of aromatic and non-aromatic amines. However, in general, suitable amines include mono-amines, such as a hydroxyamine or a polyamine so long as its molecular weight is greater than about 50 Daltons and so long as at least about 10% of its amino moieties are selected from the group consisting of primary amines, secondary amines and mixtures thereof. In one aspect of Applicants' invention, the amine comprises a primary amine moiety, and in another aspect the amine comprises, based on the total number of amine moieties in the amine, from about 10% to 100% primary amine moieties. In another aspect of Applicants' invention the amine comprises, based on the total number of amine moieties in the amine, from about 15% to 100% primary amine moieties. Suitable hydroxyamines include hydroxyamines that have an average molecular weight of greater than about 100g/mole. Specific examples of such hydroxyamines include hydroxyamines selected from the group consisting of 2-hydroxyamines, 3-hydroxyamines and mixtures thereof. Suitable polyamines include polyamines that have an average molecular weight of from about 100 to about 2.10×10^6 g/mol. In another aspect of Applicants' invention, suitable amines include amines having an Odor Intensity Index of less than that of a 1% solution of methylantranilate in dipropylene glycol.

A general structure for suitable primary amines is as follows:



wherein B is a carrier material, and n is an index of value of at least 1. Compounds containing a secondary amine group have a structure similar to the above with the exception that the compound comprises one or more -NH- groups as well as -NH₂ groups. In one aspect of Applicants' invention, the amine compound, such as certain volatile amines, will not impart a sticky feel or undesired residue to a substrate that is treated with Applicants' invention.

The hydroxy amines of the present invention have the general formula:




wherein, R¹ – R⁶ units can be any substituted or unsubstituted hydrocarbyl unit, non-limiting examples include:

- a) hydrogen;
- b) C₁-C₁₀ substituted or unsubstituted linear alkyl;
- c) C₃-C₁₀ substituted or unsubstituted branched alkyl;
- d) C₂-C₁₀ substituted or unsubstituted linear alkenyl; as in the case of α, β, γ,
- e) C₃-C₁₀ substituted or unsubstituted branched alkenyl;
- f) C₃-C₁₅ substituted or unsubstituted cycloalkyl;
- g) C₄-C₁₅ substituted or unsubstituted branched cycloalkyl;
- h) C₄-C₁₅ substituted or unsubstituted cycloalkenyl;
- i) C₅-C₁₅ substituted or unsubstituted branched cycloalkenyl;
- j) C₆-C₁₅ substituted or unsubstituted aryl;
- k) C₆-C₂₂ substituted or unsubstituted heterocyclicalkyl;
- l) C₆-C₂₂ substituted or unsubstituted heterocyclicalkenyl;
- m) and mixtures thereof;

alternatively the $R^3 - R^6$ units can be taken together to form a substituted or unsubstituted ring having in the ring from 3 to 10 carbon atoms; for example, R^3 and R^5 taken together can be fused ring comprising ketones. In one aspect of Applicants' invention, the index m is an integer from 1 to 3.

For the present invention R^7 is independently selected from any substituted or unsubstituted hydrocarbonyl unit, non-limiting embodiments are selected from the group consisting of:

- a) R^6 ;
- b) hydroxyl;
- c) a carbonyl comprising unit having the formula:




wherein R^8 is:

- i) -OH;
- ii) $-OR^9$ wherein R^9 is hydrogen, C_1 - C_{15} substituted linear alkyl, C_{11} - C_{15} unsubstituted linear alkyl, C_1 - C_{15} substituted branched alkyl, C_{11} - C_{15} unsubstituted branched alkyl, C_2 - C_{22} substituted or unsubstituted linear alkenyl, C_3 - C_{22} substituted or unsubstituted branched alkenyl, or mixtures thereof, wherein said substitution is not halogen or thioalkyl; R^9 is methyl, R^9 is hydrogen and Z is oxygen or sulfur when an oxazolidine is formed from the methyl esters of serine, threonine, cysteine, and the like;
- iii) $-N(R^{10})_2$ wherein R^{10} is hydrogen, C_1 - C_6 substituted or unsubstituted linear alkyl, C_3 - C_6 substituted or unsubstituted branched alkyl, or mixtures thereof;
- iv) C_1 - C_{22} substituted or unsubstituted linear alkyl;
- v) C_1 - C_{22} substituted or unsubstituted branched alkyl;
- vi) C_2 - C_{22} substituted or unsubstituted linear alkenyl;
- vii) C_3 - C_{22} substituted or unsubstituted branched alkenyl;
- viii) C_3 - C_{22} substituted or unsubstituted cycloalkyl;
- ix) C_6 - C_{22} substituted or unsubstituted aryl;
- x) C_6 - C_{22} substituted or unsubstituted heterocycloalkyl;

xi) C₆-C₂₂ substituted or unsubstituted heterocyclicalkenyl;
the index x is from 0 to 22;

d) alkyleneoxy units having the formula:




wherein each R¹¹ is independently;

- i) hydrogen;
- ii) -OH;
- iii) C₁-C₄ alkyl;
- iv) or mixtures thereof;


two R¹¹ units can be taken together to form a C₃-C₆ spiroannulated ring, carbonyl unit, or mixtures thereof; y has the value from 0 to 10, z has the value from 1 to 50;


e) and mixtures thereof.

In one aspect of Applicants' invention, R² and R⁷ are hydrogen. In another aspect of Applicants' invention, R¹ is selected from hydrogen and C₁-C₁₀ linear or branched alkyl. Non-limiting examples of such amines wherein m is 1 are represented by the following formula:



Non-limiting examples of suitable hydroxyamines include:





Suitable B carriers include both inorganic and organic carrier moieties. Primary amines, utilizing inorganic carriers, are those selected from mono or polymers or organic-organosilicon copolymers of amino derivatised organo silane, siloxane, silazane, alumane, aluminum siloxane, or aluminum silicate compounds. Typical examples of such carriers are: organosiloxanes with at least one primary amine moiety like the diaminoalkylsiloxane $[H_2NCH_2(CH_3)_2Si]O$, or the organoaminosilane $(C_6H_5)_3SiNH_2$ described in: Chemistry and Technology of Silicone, W. Noll, Academic Press Inc. 1998, London, pp 209, 106).

Primary amines, utilizing organic carriers, may be selected from aminoaryl derivatives, polyamines, amino acids and derivatives thereof, substituted amines and amides, glucamines, dendrimers, polyvinylamines and derivatives thereof, and/or copolymers thereof, alkylene polyamine, polyaminoacid and copolymers thereof, cross-linked polyaminoacids, amino substituted polyvinylalcohol, polyoxyethylene bis amine or bis aminoalkyl, aminoalkyl piperazine and derivatives thereof, bis (amino alkyl) alkyl diamine linear or branched, and mixtures thereof. Suitable aminoaryl derivatives are the amino-benzene derivatives including the alkyl esters of 4-amino benzoate compounds. In one aspect of Applicants' invention, suitable aminoaryl derivatives are selected from the group consisting of ethyl-4-amino benzoate, phenylethyl-4-aminobenzoate, phenyl-4-aminobenzoate, 4-amino-N'-(3-aminopropyl)-benzamide, and mixtures thereof.

Suitable polyamines include polyethyleneimines polymers, poly[oxy(methyl-1,2-ethanediyl)], α -(2-aminomethylethyl)- ω -(2-aminomethyl-ethoxy)- (= C.A.S No. 9046-10-0); poly[oxy(methyl-1,2-ethanediyl)], α -hydroxy)- ω -(2-aminomethylethoxy)-, ether with 2-ethyl-2-(hydroxymethyl)-1,3-propanediol (= C.A.S. No. 39423-51-3); commercially available from Huntsman Performance Chemicals of Houston, Texas, USA under the

tradename Jeffamines® T-403, D-230, D-400, D-2000; 2,2',2''-triaminotriethylamine; 2,2'-diamino-diethylamine; 3,3'-diamino-dipropylamine, 1,3 bis aminoethyl-cyclohexane commercially available from Mitsubishi Chemical Corporation, of 5-2, Marunouchi-2-Chome, Chiyoda-ku, Tokyo 100-0005 and the C12 Sternamines commercially available from Clariant International Ltd, Rothausstrasse 61 CH-4132 Muttenz 1/Schweiz like the C₁₂ Sternamin(propylenamine)_n with n=3/4, and mixtures thereof. In one aspect of Applicants' invention, the polyamines are polyethyleneimines commercially available from BASF Corporation 3000 Continental Drive-North Mount Olive, NJ 07828-1234 under the tradename Lupasol® like Lupasol® FG (MW 800), G20wfv (MW 1300), PR8515 (MW 2000), WF (MW 25000), FC (MW 800), G20 (MW 1300), G35 (MW 1200), G100 (MW 2000), HF (MW 25000), P (MW 750000), PS (MW 750000), SK (MW 2000000), SNA (MW 1000000). In another aspect of Applicants' invention such polyamines include Lupasol® HF or WF (MW 25000), P (MW 750000), PS (MW 750000), SK (MW 2000000), 620wfv (MW 1300) and PR 1815 (MW 2000).

Suitable amino acids for use herein may be selected from tyrosine, tryptophane, lysine, glutamic acid, glutamine, aspartic acid, arginine, asparagine, phenylalanine, proline, glycine, serine, histidine, threonine, methionine, and mixtures thereof. In one aspect of Applicants' invention suitable amino acids are selected from tyrosine, tryptophane, and mixtures thereof. In another aspect of Applicants' invention, amino acid derivatives are selected from tyrosine ethylate, glycine methylate, tryptophane ethylate, and mixtures thereof.

Suitable amines and amides for use herein may be selected from nipecotamide, N-coco-1,3-propenediamine; N-oleyl-1,3-propenediamine; N-(tallow alkyl)-1,3-propenediamine; 1,4-diamino cyclohexane; 1,2-diamino-cyclohexane; 1,12-diaminododecane, and mixtures thereof.

Other primary amine compounds suitable for use herein include glucamines. In one aspect of Applicants' invention, said glucamines are selected from 2,3,4,5,6-pentamethoxy-glucamine; 6-acetylglucamine, glucamine, and mixtures thereof.

Other suitable amine compounds include the polyethylenimine and/or polypropylenimine dendrimers and the commercially available Starburst® polyamidoamines (PAMAM) dendrimers, generation G0-G10 from Dendritech Inc. of

Dendritech, Inc. Midland, MI U.S.A. and the dendrimers Astramols[®], generation 1-5 from DSM of Geleen, The Netherlands said dendrimers being DiAminoButane PolyAmine DAB (PA)_x dendrimers with $x = 2^n \times 4$ and n being generally being between 0 and 4.

Suitable polyamino acids may contain alanine, serine, aspartic acid, arginine, valine, threonine, glutamic acid, leucine, cysteine, histidine, lysine, isoleucine, tyrosine, asparagine, methionine, proline, tryptophan, phenylalanine, glutamine, glycine or mixtures thereof. In one aspect of Applicants' invention, the required amine comprises a polyamino acid selected from the group consisting of polylysine, polyarginine, polyglutamine, polyasparagine, polyhistidine, polytryptophane or mixtures thereof. In another aspect of Applicants' invention, the required amine comprises polylysine or polyamino acids where more than 50% of the amino acids are lysine. In another aspect of Applicants' invention, the amine comprises a polyamino acid having a molecular weight of 500 to 10,000,000 Da. In another aspect of Applicants' invention, the amine comprises a polyamino acid having a molecular weight of between 2,000 and 25,000 Da. Examples and supply of polyaminoacids containing lysine, arginine, glutamine, asparagine are given in the Bachem 1996, Peptides and Biochemicals catalog. For example polylysine can be supplied as polylysine hydrobromide. Polylysine hydrobromide is commercially available from Sigma, Applichem, Bachem and Fluka.

Suitable amines also include ethoxylated polylysine, provided a requisite amount of primary amino groups remains in the polymer; crosslinked polyamino acids and co-polymerized polyamino acids and amino acids. Although crosslinked polyamino acids are useful, such acids need to have free primary and/or secondary amino groups. In one aspect of Applicants' invention, the amine comprises a crosslinked polyamino acid having a molecular weight of 20,000 to 10,000,000 Da. In another aspect of Applicants' invention, the amine comprises a crosslinked polyamino acid having a molecular weight of between 200,000 and 2,000,000 Da.

Suitable co-polymerized polyamino acids and amino acids may be co-polymerized with acids, amides, acyl chlorides such as aminocaproic acid, adipic acid, ethylhexanoic acid, caprolactam or mixtures thereof. The molar ratio used in these copolymers typically ranges from 1:1 (reagent/ amino acid (lysine)) to 1:20, or from 1:1 to 1:10.

Non-limiting examples of suitable chemically modified amino acids include benzyloxycarbonyl, aminobutyric acid, butyl ester, pyroglutamic acid. More examples of common modifications of amino acids and small amino acid fragments can be found in the Bachem, 1996, Peptides and Biochemicals Catalog. In chemically modified amino acids, the amine or acidic function of the amino acid has typically reacted with a chemical reagent.

Non-limiting examples of suitable amino functional polymers that contain at least one primary amine group include:

- Polyvinylamine with a MW of about 300-2.10E6 Da;
- Polyvinylamine alkoxylated with a MW of about 600, 1200 or 3000 Da and an ethoxylation degree of 0.5;
- Polyvinylamine vinylalcohol - molar ratio 2:1, polyvinylaminevinylformamide - molar ratio 1:2 and polyvinylamine vinylformamide-molar ratio 2:1;
- Triethylenetetramine, diethylenetriamine, tetraethylenepentamine;
- Bis-aminopropylpiperazine;
- Polyamino acid (L-lysine / lauric acid in a molar ratio of 10/1), Polyamino acid (L-lysine / aminocaproic acid / adipic acid in a molar ratio of 5/5/1), Polyamino acid (L-lysine / aminocaproic acid / ethylhexanoic acid in a molar ratio of 5/3/1) Polyamino acid (polylysine-cocaprolactam); Polylysine; Polylysine hydrobromide; cross-linked polylysine,
- amino substituted polyvinylalcohol with a MW ranging from 400 Da to 300,000 Da;
- polyoxyethylene bis [amine] available from e.g. Sigma;
- polyoxyethylene bis [6-aminohexyl] available from e.g. Sigma;
- N,N'-bis-(3-aminopropyl)-1,3-propanediamine linear or branched (TPTA);
- N,N'-bis-(3-aminopropyl)ethylenediamine; and
- 1,4-bis-(3-aminopropyl) piperazine (BNPP).

In one aspect of Applicants' invention, amines are selected from ethyl-4-amino benzoate, polyethyleneimine polymers commercially available from BASF Corporation 3000 Continental Drive-North Mount Olive, NJ 07828-1234 under the tradename Lupasol® like Lupasol® HF, P, PS, SK, SNA, WF, G20wfv and PR8515; the diaminobutane dendrimers Astramol®, polylysine, cross-linked polylysine, N,N'-bis-(3-

aminopropyl)-1,3-propanediamine linear or branched; 1,4-bis-(3-aminopropyl) piperazine, and mixtures thereof. In another aspect of Applicants' invention, amines are selected from ethyl-4-amino benzoate, polyethyleneimine polymers having a molecular weight greater than 200 Da including those commercially available from BASF Corporation 3000 Continental Drive-North Mount Olive, NJ 07828-1234 under the tradename Lupasol® like Lupasol® HF, P, PS, SK, SNA, WF, G20wfv and PR8515; polylysine, cross-linked polylysine, N,N'-bis-(3-aminopropyl)-1,3-propanediamine linear or branched, 1,4-bis-(3-aminopropyl) piperazine, and mixtures thereof.

Benefit Agent

Another essential component of the benefit agent delivery systems herein is a benefit agent. The benefit agents essentially used to form the delivery systems of this invention must be in the form of an aldehyde or ketone. It is understood that the genus of ketones includes those ketones, such as damascone, that comprise enone moieties. Such benefit agent can, for example, be selected from a flavor ketone or aldehyde, a pharmaceutical ketone or aldehyde, a biocontrol ketone or aldehyde, a perfume ketone or aldehyde and mixtures thereof. Perfume ketones and aldehydes are the most typical benefit agent used in Applicants' invention. A typical disclosure of suitable ketone and/or aldehydes, traditionally used in perfumery, can be found in "perfume and Flavor Chemicals", Vol. I and II, S. Arctander, Allured Publishing, 1994, ISBN 0-931710-35-5. This publication is also incorporated herein by reference.

The perfume ketones utilized in the benefit agent delivery systems herein can comprise any material which is chemically a ketone and which can impart a desirable odor or freshness benefit to surfaces. The perfume ketone component can, of course, comprise more than one ketone, i.e., mixtures of ketones. In one aspect of Applicants' invention, the perfume ketone is selected from the group consisting of buccoxime; iso jasmone; methyl beta naphthyl ketone; musk indanone; tonalid/musk plus; Alpha-Damascone, Beta-Damascone, Delta-Damascone, Iso-Damascone, Damascenone, Damarose, Methyl-Dihydrojasmonate, Menthone, Carvone, Camphor, Fenchone, Alpha-Ionone, Beta-Ionone, dihydro-Beta-Ionone, Gamma-Methyl so-called Ionone, Fleuramone, Dihydrojasmone, Cis-Jasmone, Iso-E-Super, Methyl- Cedrenyl-ketone or

Methyl- Cedrylone, Acetophenone, Methyl-Acetophenone, Para-Methoxy-Acetophenone, Methyl-Beta-Naphtyl-Ketone, Benzyl-Acetone, Benzophenone, Para-Hydroxy-Phenyl-Butanone, Celery Ketone or Livescone, 6-Isopropyldecahydro-2-naphtone, Dimethyl-Octenone, Freskomenthe, 4-(1-Ethoxyvinyl)-3,3,5,5,-tetramethyl-Cyclohexanone, Methyl-Heptenone, 2-(2-(4-Methyl-3-cyclohexen-1-yl)propyl)-cyclopentanone, 1-(p-Menthen-6(2)-yl)-1-propanone, 4-(4-Hydroxy-3-methoxyphenyl)-2-butanone, 2-Acetyl-3,3-Dimethyl-Norbornane, 6,7-Dihydro-1,1,2,3,3-Pentamethyl-4(5H)-Indanone, 4-Damascol, Dulcinyll or Cassione, Gelsone, Hexalon, Isocyclemon E, Methyl Cyclocitrone, Methyl-Lavender-Ketone, Orivon, Para-tertiary-Butyl-Cyclohexanone, Verdone, Delphone, Muscone, Neobutenone, Plicatone, Veloutone, 2,4,4,7-Tetramethyloct-6-en-3-one, Tetrameran, hedione, and mixtures thereof. While in another aspect of Applicants' invention the perfume ketones is selected from the group consisting of Alpha Damascone, Delta Damascone, Iso Damascone, Carvone, Gamma-Methyl-Ionone, Iso-E-Super, 2,4,4,7-Tetramethyloct-6-en-3-one, Benzyl Acetone, Beta Damascone, Damascenone, methyl dihydrojasmonate, methyl cedrylone, hedione, and mixtures thereof.

Suitable perfume aldehydes can comprise any perfume material that is chemically an aldehyde, which can, like the perfume ketone component, impart a desirable odor or freshness benefit to surfaces. As with the perfume ketone benefit agents, the perfume aldehyde benefit agent component can comprise a single individual aldehyde or mixtures of two or more perfume aldehydes. Suitable perfume aldehyde materials for use in the delivery systems herein, whether by themselves or as part of a perfume aldehyde mixture, include melonal, triplal, Lugustral, adoxal; anisic aldehyde; cymal; ethyl vanillin; florhydral; helional; heliotropin; hydroxycitronellal; koavone; lauric aldehyde; lyral; methyl nonyl acetaldehyde; P. T. buccinal; phenyl acetaldehyde; undecylenic aldehyde; vanillin; 2,6,10-trimethyl-9-undecenal, 3-dodecen-1-al, alpha-n-amylic cinnamic aldehyde, 4-methoxybenzaldehyde, benzaldehyde, 3-(4-tert butylphenyl)-propanal, 2-methyl-3-(para-methoxyphenyl) propanal, 2-methyl-4-(2,6,6-trimethyl-2(1)-cyclohexen-1-yl) butanal, 3-phenyl-2-propenal, cis-/trans-3,7-dimethyl-2,6-octadien-1-al, 3,7-dimethyl-6-octen-1-al, [(3,7-dimethyl-6-octenyl)oxy] acetaldehyde, 4-isopropylbenzaldehyde, 1,2,3,4,5,6,7,8-octahydro-8,8-dimethyl-2-naphthaldehyde, 2,4-dimethyl-3-cyclohexen-1-

carboxaldehyde, 2-methyl-3-(isopropylphenyl)propanal, 1-decanal; decyl aldehyde, 2,6-dimethyl-5-heptenal, 4-(tricyclo[5.2.1.0(2,6)]-decylidene-8)-butanal, octahydro-4,7-methano-1H-indenecarboxaldehyde, 3-ethoxy-4-hydroxy benzaldehyde, para-ethyl-alpha, alpha-dimethyl hydrocinnamaldehyde, alpha-methyl-3,4-(methylenedioxy)-hydrocinnamaldehyde, 3,4-methylenedioxybenzaldehyde, alpha-n-hexyl cinnamic aldehyde, m-cymene-7-carboxaldehyde, alpha-methyl phenyl acetaldehyde, 7-hydroxy-3,7-dimethyl octanal, Undecenal, 2,4,6-trimethyl-3-cyclohexene-1-carboxaldehyde, 4-(3)(4-methyl-3-pentenyl)-3-cyclohexen-carboxaldehyde, 1-dodecanal, 2,4-dimethyl cyclohexene-3-carboxaldehyde, 4-(4-hydroxy-4-methyl pentyl)-3-cyclohexene-1-carboxaldehyde, 7-methoxy-3,7-dimethyloctan-1-al, 2-methyl undecanal, 2-methyl decanal, 1-nonanal, 1-octanal, 2,6,10-trimethyl-5,9-undecadienal, 2-methyl-3-(4-tertbutyl)propanal, dihydrocinnamic aldehyde, 1-methyl-4-(4-methyl-3-pentenyl)-3-cyclohexene-1-carboxaldehyde, 5 or 6 methoxyhexahydro-4,7-methanoindan-1 or 2-carboxaldehyde, 3,7-dimethyloctan-1-al, 1-undecanal, 10-undecen-1-al, 4-hydroxy-3-methoxy benzaldehyde, 1-methyl-3-(4-methylpentyl)-3-cyclohexenecarboxaldehyde, 7-hydroxy-3,7-dimethyl-octanal, trans-4-decenal, 2,6-nonadienal, para-tolylacetaldehyde; 4-methylphenylacetaldehyde, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-butenal, ortho-methoxycinnamic aldehyde, 3,5,6-trimethyl-3-cyclohexene carboxaldehyde, 3,7-dimethyl-2-methylene-6-octenal, phenoxyacetaldehyde, 5,9-dimethyl-4,8-decadienal, peony aldehyde (6,10-dimethyl-3-oxa-5,9-undecadien-1-al), hexahydro-4,7-methanoindan-1-carboxaldehyde, 2-methyl octanal, alpha-methyl-4-(1-methyl ethyl) benzene acetaldehyde, 6,6-dimethyl-2-norpinene-2-propionaldehyde, para methyl phenoxy acetaldehyde, 2-methyl-3-phenyl-2-propen-1-al, 3,5,5-trimethyl hexanal, Hexahydro-8,8-dimethyl-2-naphthaldehyde, 3-propyl-bicyclo[2.2.1]-hept-5-ene-2-carbaldehyde, 9-decenal, 3-methyl-5-phenyl-1-pentanal, methylnonyl acetaldehyde, 1-p-menthene-q-carboxaldehyde, citral, linal and mixtures thereof. In one aspect of Applicants' invention perfume aldehydes are selected from the group consisting of citral, 1-decanal, benzaldehyde, florhydral, 2,4-dimethyl-3-cyclohexen-1-carboxaldehyde; cis/trans-3,7-dimethyl-2,6-octadien-1-al; heliotropin; 2,4,6-trimethyl-3-cyclohexene-1-carboxaldehyde; 2,6-nonadienal; alpha-n-amyl cinnamic aldehyde, alpha-n-hexyl

cinnamic aldehyde, P.T. Bucinal, lylal, cymal, methyl nonyl acetaldehyde, trans-2-nonenal, lilial, trans-2-nonenal, and mixtures thereof.

Other suitable benefit agents include flavor ingredients including spices or flavor enhancers that contribute to the overall flavor perception of the product into which the benefit agent delivery system is incorporated. Pharmaceutical benefit agents including drugs. In one aspect of Applicants' invention a therapeutically acceptable amount of drug is employed. Biocontrol agents including biocides, antimicrobials, bactericides, fungicides, algacides, mildewcides, disinfectants, sanitizer-like bleaches, antiseptics, insecticides, insect and/or moth repellant, vermicides, plant growth hormones, and the like. Antimicrobials including glutaraldehyde, cinnamaldehyde, and mixtures thereof. Typical insect and/or moth repellants such as citronellal, citral, N, N diethyl meta toluamide, Rotundial, 8-acetoxycarvotanacenone, and mixtures thereof. Other examples of insect and/or moth repellant for use as benefit agents herein are disclosed in US 4,449,987, 4,693,890, 4,696,676, 4,933,371, 5,030,660, 5,196,200, and "Semio Activity of Flavor and Fragrance molecules on various Insect Species", B.D. Mookherjee et al., published in Bioactive Volatile Compounds from Plants, ASC Symposium Series 525, R. Teranishi, R.G. Buttery, and H. Sugisawa, 1993, pp. 35-48. These publications are incorporated herein by reference.

Delivery System Forms

The benefit agent delivery systems herein may be based on the formation of a liquid or granular matrix. "Liquids" include fluids of density and viscosity that are conventional for liquids as well as gels and foams. Useful liquids may be aqueous or non-aqueous. Water is typically the major component of the delivery systems that are in aqueous liquid form. Conventional non-aqueous solvents may be used to form the matrix for liquid delivery systems in non-aqueous form. Liquid products, i.e., those containing 10% or greater of water or other solvents, are highly preferred.

Delivery systems in granular form can be fashioned from any type of solid-state material that comprises particles or granules ranging in size from 1 μm to 100 μm . Thus the granular matrix can include particles ranging from very fine powder to agglomerates or tablets. The granular matrix furthermore can comprise either inert or active

ingredients, or both, with respect to the function of the product into which the delivery system is to be incorporated.

Most typically, the liquid or granular matrix used to form the delivery systems herein will comprise the matrix for the liquid or granular end product into which the benefit agent delivery system will be incorporated and made a part of. Thus, for example, liquid or granular detergent compositions for laundry or hard surface cleaning will frequently comprise the liquid or granular matrix into which the amine-based compounds and benefit agents described herein will be separately added to form the delivery systems of this invention.

Delivery System Preparation

It is an essential feature of the present invention that the amine compound and the benefit agent be added such that substantially no chemical reaction occurs between these materials prior to their contact with the liquid or granular matrix. For purposes of this invention, the amine-based compound and benefit agent are separately added to the system-forming matrix if the entire amounts of these components are combined with the matrix as discrete components. In particular, there must be essentially no chemical reaction between these two materials before they are combined with the matrix. Thus the amine compound and the benefit agent may be added to the matrix at separate times and/or from separate containers or from separate holding or delivery means. The amine compound and the benefit agent materials may even be mixed together prior to combination with the system-forming matrix so long as substantially no chemical reaction occurs between these materials prior to their contact with the system-forming matrix.

The benefit agent delivery system, especially in a granular form, can be prepared by simply admixing the amine-based compound and the benefit agent ketone and/or aldehyde under conditions which are sufficient to bring about combination, e.g., thorough admixture, of these components with the liquid or granular matrix. Frequently this admixing is carried out using high shear agitation. Temperatures of from about 40 °C to 65 °C may be utilized. Additional materials may also be added to the matrix in order to form the complete end product into which the delivery system is to be incorporated.

On a weight basis, the ratio of amine to benefit agent can vary widely, typically greater than about 1:5, more typically from about 1000:1 to about 1:1 for the two essential components. (amine compound and ketone/aldehyde benefit agent). In general, an excess of amine is desirable.

Adjunct Ingredients

Applicants' the various forms of Applicants' delivery system may contain adjunct ingredients including but not limited to water, surfactant, colorants and mixtures thereof.

Containers

Applicants' delivery may comprise one or more containers capable of containing the benefit agent and amine of the present invention in physical contact or sufficiently separate such that the benefit agent and amine are not in physical contact. Such one or more containers have separate compartments that may be employed to contain benefit agent and amine of the present invention in such a manner as to keep said benefit agent and amine sufficiently separate such that the benefit agent and amine are not in physical contact. One or more of said containers may comprise one or more spray dispensers capable of capable of dispensing said benefit agent and amine together or separately.

EXAMPLE

Ingredients	Weight %			
	1	2	3	4
Pro-fragrance component				
Pro-fragrance ¹	1.0	--	--	--
Pro-fragrance ²	2.0	--	--	--
Pro-fragrance ³	2.0	--	--	--
Free fragrance component				
Damascone	0.0001	0.015	--	0.01
Melonal	0.05	0.02	--	--
Triplal	0.01	0.03	--	--
Beta-ionone	0.01	--	--	--
Additional free fragrance raw materials containing at least one aldehyde / ketone ⁴	13.8	15.2	17.0	15.1
Amine according to present invention	0.09	0.5	1.5	0.03
Carrier ⁵	balance	balance	balance	balance

1. Pro-fragrance which releases delta-damascone.
2. Pro-fragrance which releases melonal.
3. Pro-fragrance which releases triplal.
4. Conventional fragrance accord.
5. Ethanol:water mixture (between 100:0 and 50:50).

WHAT IS CLAIMED IS:

1. A benefit agent delivery system suitable for delivering a benefit agent to a substrate, wherein the benefit agent delivery system comprises a benefit agent and an amine comprising a primary and/or secondary amine moiety, preferably a primary amine, preferably 10% primary amines, more preferably 15% primary amines such that when said amine and said benefit agent are directly applied to a substrate, the benefit agent provides a benefit to the substrate for a longer period of time than when said amine is not present.
2. The benefit agent delivery system according to Claim 1 wherein the amine comprises a hydroxy moiety, preferably a mixture of amines comprising at least one of 2-hydroxyamine or 3-hydroxyamine.
3. A benefit agent delivery system according any preceding claim wherein
 - a.) said benefit agent is selected from a perfume aldehyde, perfume ketone and mixtures thereof; and
 - b.) said benefit agent delivery system, when directly applied to a substrate, providing a benefit to the substrate for a longer period of time, as determined by Applicants' Test Protocol 1.1, than when said amine is not present.
4. The benefit delivery system of any preceding claim wherein said system comprises a sufficient amount of adjunct ingredients such that said benefit delivery system is a fine fragrance, home care perfume or freshening product, hard surface treating composition, beauty care product or hair care product.
5. The benefit agent delivery system according to any preceding claim comprising one or more containers and wherein the benefit agent and amine are

- a.) present in a single container in physical contact with each other; or separated from each other in a single container sufficiently such that said benefit agent and said amine are not in physical contact; or
 - b.) present in separate discrete containers.
6. The benefit agent delivery system according to Claim 4 wherein each container comprises at least one spray dispenser, said spray dispenser being capable of dispensing said benefit agent and amine:
- a.) together; or
 - b.) separately.
7. A method of applying a benefit agent comprising a perfume aldehyde, perfume ketone and mixtures thereof to a substrate comprising contacting said substrate with said benefit agent before, during or after contacting said with an amine comprising a primary amine moiety, a secondary amine moiety and mixtures thereof; said method preferably comprising directly contacting the substrate with the benefit agent delivery system of any preceding claim.
8. A benefit-containing substrate produced by the method of Claim 7.
9. A benefit agent delivery system comprising
- a.) a benefit agent selected from the group consisting of perfume aldehydes, perfume ketones and mixtures thereof; preferably selected from the group consisting of Alpha Damascone, Delta Damascone, Iso Damascone, Carvone, Gamma-Methyl-Ionone, Iso-E-Super, 2,4,4,7-Tetramethyl-oct-6-en-3-one, Benzyl Acetone, Beta Damascone, Damascenone, methyl dihydrojasmonate, methyl cedrylone, hedione, citral, 1-decanal, benzaldehyde, florhydral, 2,4-dimethyl-3-cyclohexen-1-carboxaldehyde; cis/trans-3,7-dimethyl-2,6-octadien-1-al; heliotropin; 2,4,6-trimethyl-3-cyclohexene-1-carboxaldehyde; 2,6-nonadienal; alpha-n-amyl cinnamic aldehyde, alpha-n-hexyl cinnamic

aldehyde, P.T. Bucinal, lyral, cymal, methyl nonyl acetaldehyde, trans-2-nonenal, lilial, trans-2-nonenal, and mixtures thereof; and

- b.) a non-aromatic amine having a molecular weight greater than about 50 Daltons and at least about 10% of its amino moieties selected from the group consisting of primary amines, secondary amines and mixtures thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/33377

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C11D3/50 A61L9/01 C11D3/30 C11D3/33 C11D3/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C11D A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 103 678 A (MASSCHELEIN AXEL ET AL) 15 August 2000 (2000-08-15) claims 1-9,22 examples 1,2,4 column 2, line 12 - column 15, line 7 column 34, line 48 - line 53 column 35, line 34 - line 45	1-9
X	US 6 153 567 A (HUGHES IAIN ALLAN) 28 November 2000 (2000-11-28) claims 1-11 examples column 2, line 50 - line 56 -- -/-	1,3-5, 7-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

20 February 2003

Date of mailing of the international search report

27/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Neys, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/33377

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 985 402 A (NARULA ANUBHAV P S ET AL) 15 January 1991 (1991-01-15) abstract claims 5,7,8 examples I,III(a),IV-XX column 13, line 3 - line 20 ----	1-8
X	US 4 990 494 A (NARULA ANUBHAV P S ET AL) 5 February 1991 (1991-02-05) abstract claims 2,4,6,8 examples I,III(a),IV-XX column 13, line 16 - line 25 ----	1-8
X	EP 0 864 642 A (PROCTER & GAMBLE) 16 September 1998 (1998-09-16) abstract claims 1-4,13,14 examples page 3, line 37 -page 13, line 31 page 24, line 43 - line 49 ----	1,4-6
P,X	WO 01 93823 A (QUEST INTERNATIONAL B.V.) 13 December 2001 (2001-12-13) claims examples page 3, paragraph 4 page 11, paragraph 1 -page 12, last paragraph page 8, last paragraph ----	1,3-8
A	EP 1 116 788 A (PROCTER & GAMBLE) 18 July 2001 (2001-07-18) the whole document ----	1-9
A	EP 1 067 173 A (PROCTER & GAMBLE) 10 January 2001 (2001-01-10) the whole document -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/33377

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6103678	A	15-08-2000	BR 9712897 A EP 0841391 A1 JP 2001503803 T WO 9820102 A1	21-03-2000 13-05-1998 21-03-2001 14-05-1998
US 6153567	A	28-11-2000	AU 4465296 A AU 726938 B2 AU 4744899 A BR 9510277 A CA 2208371 A1 CN 1170352 A CZ 9701884 A3 EP 0794763 A1 HU 77478 A2 JP 10511093 T NZ 298935 A PL 321858 A1 SK 83397 A3 TR 960613 A2 WO 9619194 A1	10-07-1996 23-11-2000 11-11-1999 06-01-1998 27-06-1996 14-01-1998 12-11-1997 17-09-1997 28-05-1998 27-10-1998 28-10-1999 22-12-1997 14-01-1998 21-07-1996 27-06-1996
US 4985402	A	15-01-1991	CA 2034784 A1 DE 69118422 D1 DE 69118422 T2 DE 440362 T1 EP 0440362 A1	03-08-1991 09-05-1996 17-10-1996 11-06-1992 07-08-1991
US 4990494	A	05-02-1991	CA 2034784 A1 DE 69118422 D1 DE 69118422 T2 DE 440362 T1 EP 0440362 A1	03-08-1991 09-05-1996 17-10-1996 11-06-1992 07-08-1991
EP 0864642	A	16-09-1998	EP 0864642 A1 BR 9808015 A CN 1255158 T WO 9841605 A1 JP 2001515547 T	16-09-1998 08-03-2000 31-05-2000 24-09-1998 18-09-2001
WO 0193823	A	13-12-2001	AU 6049401 A WO 0193823 A1	17-12-2001 13-12-2001
EP 1116788	A	18-07-2001	EP 1116788 A1 AU 3089401 A BR 0107549 A CN 1394231 T EP 1246899 A1 WO 0151599 A1	18-07-2001 24-07-2001 08-10-2002 29-01-2003 09-10-2002 19-07-2001
EP 1067173	A	10-01-2001	EP 1067173 A1 AU 5916000 A WO 0104247 A1	10-01-2001 30-01-2001 18-01-2001

THIS PAGE BLANK (USPTO)